# A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer

> **NCT01383707** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 77 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Bevacizumab
- **DRUG:** Levofolinic acid
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01383707
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-12
- **Primary completion:** 2014-05-28
- **Final completion:** 2016-05-18
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01383707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01383707, "A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01383707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*